# US 2023/0068124 A1 · Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068124 A1
- Document ID: US20230068124A1
- Status: Published application
- Kind: A1
- Application number: 17/874,122
- Filed: 2022-07-26
- Published: 2023-03-02
- Earliest claimed: 2012-11-16
- Assignees: Redwood Bioscience, Inc.
- Applicants: Redwood Bioscience, Inc.
- Inventors: Romas Alvydas Kudirka; Aaron Edward Albers; Robyn M. Barfield; David Rabuka
- Web page: https://patentgrep.com/patent/US20230068124A1

## CPC

- G01N 33/582: {with fluorescent label}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0058: {Antibodies}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

## Claims

### Claim 1

A conjugate comprising:
at least one modified amino acid residue of formula (111):
wherein
n is 0 or 1;
R1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
R2 and R3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
X1, X2, X3 and X4 are each independently selected from C, N, O and S;
Y1, Y2, Y3, and Y5 are each independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
L is an optional linker,
wherein one of W1 and W2 is a polypeptide and the other is a drug or a detectable label.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein n is 1.

### Claim 5 (depends on 1)

The conjugate of claim 1, wherein R2 and R3 are each independently selected from alkyl and substituted alkyl.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein R2 and R3 are each methyl.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein X1, X2, X3 and X4 are each C.

### Claim 8 (depends on 1)

The conjugate of claim 1, wherein Y1, Y2, Y3 and Y5 are each H.

### Claim 9 (depends on 1)

The conjugate of claim 1, wherein L is present and comprises a group selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl amino, alkylamide, substituted alkylamide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

### Claim 10 (depends on 1)

The conjugate of claim 1, wherein L is present and comprises a polymer.

### Claim 11 (depends on 10)

The conjugate of claim 10, wherein the polymer is a polyethylene glycol.

### Claim 12 (depends on 1)

The conjugate of claim 1, wherein the detectable label comprises a fluorophore.

### Claim 13 (depends on 1)

The conjugate of claim 1, wherein W1 is the drug or the detectable label, and W2 is the polypeptide.

### Claim 14 (depends on 1)

The conjugate of claim 1, wherein W1 is the polypeptide, and W2 is the drug or the detectable label.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises at least one modified amino acid residue of formula (IIIa):

### Claim at position 19

-41. (canceled)

### Claim 42 (depends on 1)

A pharmaceutical composition comprising:
a conjugate of claim 1; and
a pharmaceutically acceptable excipient.

### Claim 43 (depends on 1)

A method of delivering a conjugate to a subject, the method comprising:
administering to the subject an effective amount of a conjugate of claim 1.

### Claim 44 (depends on 1)

A method of treating a condition in a subject, the method comprising:
administering to the subject having the condition a therapeutically effective amount of a pharmaceutical composition comprising a conjugate of claim 1, wherein the administering is effective to treat the condition in the subject.
